POUR, Luděk, Hana ŠVÁCHOVÁ, Pavel NĚMEC, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ, Michal HOLÁNEK, Lucie KOVÁŘOVÁ, Lenka ZAHRADOVÁ, Miroslav PENKA and Roman HÁJEK. High Trombospondin Level Correlates Closely with Poor Response to Bortezomib Treatment. In XIIth International myeloma workshop. 2009. ISBN 1557-9190.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name High Trombospondin Level Correlates Closely with Poor Response to Bortezomib Treatment
Name in Czech Vysoké hladiny trombospondinu korelují se špatnou odpovědí na léčbu bortezomibem
Authors POUR, Luděk, Hana ŠVÁCHOVÁ, Pavel NĚMEC, Zdeněk ADAM, Marta KREJČÍ, Viera SANDECKÁ, Michal HOLÁNEK, Lucie KOVÁŘOVÁ, Lenka ZAHRADOVÁ, Miroslav PENKA and Roman HÁJEK.
Edition XIIth International myeloma workshop, 2009.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Medicine
ISBN 1557-9190
Keywords in English multiple myeloma;bortezomib;trombospondin
Tags bortezomib, multiple myeloma, trombospondin
Tags International impact
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 2/4/2009 18:08.
Abstract
High Trombospondin Level Correlates Closely with Poor Response to Bortezomib Treatment
Abstract (in Czech)
Vysoké hladiny trombospondinu korelují se špatnou odpovědí na léčbu bortezomibem
Links
LC06027, research and development projectName: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622434, plan (intention)Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
PrintDisplayed: 2/5/2024 20:08